PMID- 30638182
OWN - NLM
STAT- MEDLINE
DCOM- 20190617
LR  - 20200225
IS  - 1976-670X (Electronic)
IS  - 1976-6696 (Print)
IS  - 1976-6696 (Linking)
VI  - 52
IP  - 2
DP  - 2019 Feb
TI  - Regulation of post-translational modification in breast cancer treatment.
PG  - 113-118
AB  - The small ubiquitin-related modification molecule (SUMO), one of the 
      post-translational modification molecules, is involved in a variety of cellular 
      functions where it regulates protein activity and stability, transcription, and 
      cell cycling. Modulation of protein SUMOylation or deSUMOylation modification has 
      been associated with regulation of carcinogenesis in breast cancer. In the 
      dynamic processes of SUMOylation and deSUMOylation in a variety of cancers, SUMO 
      proteases (SENPs), reverse SUMOylation by isopeptidase activity and SENPs are 
      mostly elevated, and are related to poor patient prognosis. Although underlying 
      mechanisms have been suggested for how SENPs participate in breast cancer 
      tumorigenesis, such as through regulation of target protein transactivation, 
      cancer cell survival, cell cycle, or other post-translational 
      modification-related machinery recruitment, the effect of SENP isoform-specific 
      inhibitors on the progression of breast cancer have not been well evaluated. This 
      review will introduce the functions of SENP1 and SENP2 and the underlying 
      signaling pathways in breast cancer for use in discovery of new biomarkers for 
      diagnosis or therapeutic targets for treatment. [BMB Reports 2019; 52(2): 
      113-118].
FAU - Heo, Kyung-Sun
AU  - Heo KS
AD  - College of Pharmacy and Institute of Drug Research and Development, Chungnam 
      National University, Daejeon 34134, Korea.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Korea (South)
TA  - BMB Rep
JT  - BMB reports
JID - 101465334
RN  - 0 (Small Ubiquitin-Related Modifier Proteins)
RN  - EC 3.4.- (Peptide Hydrolases)
RN  - EC 3.4.- (SENP1 protein, human)
RN  - EC 3.4.22.- (Cysteine Endopeptidases)
RN  - EC 3.4.22.- (SENP2 protein, human)
SB  - IM
EIN - BMB Rep. 2019 Dec;52(12):728. PMID: 31878989
MH  - Breast Neoplasms/*genetics/metabolism
MH  - Cysteine Endopeptidases/metabolism
MH  - Female
MH  - Humans
MH  - Peptide Hydrolases/metabolism
MH  - Protein Processing, Post-Translational/genetics/physiology
MH  - Signal Transduction
MH  - Small Ubiquitin-Related Modifier Proteins/genetics/metabolism
MH  - Sumoylation/*physiology
PMC - PMC6443327
COIS- CONFLICTS OF INTEREST The authors have no conflicting interests.
EDAT- 2019/01/15 06:00
MHDA- 2019/06/18 06:00
PMCR- 2019/03/01
CRDT- 2019/01/15 06:00
PHST- 2018/11/01 00:00 [received]
PHST- 2019/01/15 06:00 [pubmed]
PHST- 2019/06/18 06:00 [medline]
PHST- 2019/01/15 06:00 [entrez]
PHST- 2019/03/01 00:00 [pmc-release]
AID - 4499 [pii]
AID - bmb-52-113 [pii]
AID - 10.5483/BMBRep.2019.52.2.017 [doi]
PST - ppublish
SO  - BMB Rep. 2019 Feb;52(2):113-118. doi: 10.5483/BMBRep.2019.52.2.017.